EXHIBIT 10.5
ims
12th March 2003
Adrian Kemp
AstraZeneca plc
Legal & Secretary's Department
Room 3.10, Stanhope Gate
15 Stanhope Gate
London W1K 1LN
Dear Adrian,
IMS Data Disclosure for Annual Report
In connection with AstraZeneca's anticipated filing of certain registration
statements IMS HEALTH hereby authorizes you to refer to IMS HEALTH and Certain
pharmaceutical industry data derived by IMS HEALTH, as identified on the pages
annexed hereto as Exhibit A, a selection of pages from AstraZeneca's Annual
Report for the fiscal year ended 2002 (the "Annual Report", which is
incorporated by reference in the registration statement No. 33-83774 on Form
F-3, for AstraZencca group and Zeneca Wilmington Inc., and in the registration
statements No. 333-09060, No. 333-09062, No. 333-65362, No. 33-65366, No.
333-12310, No. 333-12426, No. 333-12428, No. 333-13328 and No. 333-13918 on Form
S-8 for AstraZeneca Plc. A copy of the relevant pages of the Annual Report has
been provided to IMS HEALTH.
Our authorization is subject to your acknowledgment and agreement that:
1) IMS HEALTH has not been provided with a full copy of the draft Annual
Report but only a very limited number of pages from the documents as
indicated above;
2) IMS HEALTH has not undertaken an independent review of the information
disclosed in the Annual Report other than to discuss our observations as
to the accuracy of the information relating to IMS HEALTH and certain
pharmaceutical industry data derived by IMS HEALTH; and
3) AstraZeneca accepts full responsibility for the disclosure of all
information and data, including that relating to IMS HEALTH, set forth in
the Annual Report as filed with the SEC and agrees to indemnify IMS HEALTH
from any third party claims that may arise therefrom.
Please indicate your agreement to the foregoing by signing in the space
indicated below. Our authorisation will not become effective until accepted and
agreed by AstraZeneca.
Very truly yours,
/s/ Paul Jenner
Paul Jenner, Director Communications and Marketing Services
For and on behalf of IMS HEALTH
IMS Health Tel +44(0)20 7393-5000 IMS A.G. registered &
7 Harewood Avenue Fax+44(0)20 7393-5900 incorporated with
London NWI 6JB limited liability in
United Kingdom Zug, Switzerland,
registered as a branch
in England, Ref. No.
BR 1589, Swiss address
Dorfplatz 4, 6330 CHAM.
ims
ACCEPTED AND AGREED
THIS 20TH DAY OF MARCH 2003:
AstraZeneca
By: /s/ Adrian C N Kemp
------------------------------------
Name: Adrian C N Kemp
----------------------------------
Title: Assistant Secretary
----------------------------------
Appendix A: Selection of pages in Annual Report
IMS Health Tel +44(0)20 7393-5000 IMS A.G. registered &
7 Harewood Avenue Fax+44(0)20 7393-5900 incorporated with
London NWI 6JB limited liability in
United Kingdom Zug, Switzerland,
registered as a branch
in England, Ref. No.
BR 1589, Swiss address
Dorfplatz 4, 6330 CHAM.
EXHIBIT A
Annotations from Final version Feb 20 2003 IMS.pdf
Page 3
- --------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date: 2003-02-20 13:45:12
Nexium NRX and TRX US
Page 7
- --------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date; 2003-02-20 13:46:21
Seroquel US (N5A1);
Atacand global (Excl Japan) C9C+C9D
Page 10
- --------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date: 2003-02-20 13:46:59
US market size and growth
Page 12
- --------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date: 2003-02-20 13:47:55
Global market (32 countries) growth:
Selected markets share and growth
Annotation 2: Label: BaseInstaller: Date: 2003-02-20 13:48:50
Top5 and top10 corporations share of global
Page 13
- --------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date: 2003-02-20 13:49:18
A2B2 market size
Annotation 2; Label: BaseInstaller; Date: 2003-02-20 13:51:06
US - Nexium overtake Losec RX;
Nexium global and US share of A2B2
Annotation 3; Label: BaseInstaller; Date: 2003-02-20 13:51:23
Losec US and global share
Page 14
- --------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date: 2003-02-20 13:56:14
CV treatment: C, B1, B2, A8A, A10
Annotation 2; Label; BaseInstaller; Date: 2003-02-20 13:57:05
Atacand, C9C+C9D
31 countries
Annotation 3; Label: BaseInstaller; Date: 2003-02-20 13:58:05
Atacand C9C+C9D
Annotation 4; Label: BaseInstaller; Date: 2003-02-20 14:01:35
Intprd Betaloc
Annotation 5; Label: BaseInstaller; Date: 2003-02-20 14:02:59
Zestril family: Zestril, Zestoretic, (C9A+C9B)
Annotation 6; Label: BaseInstaller; Date: 2003-02-20 14:04:12
Statin market: ClOAl
Page 15
- --------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date: 2003-02-20 14:07:10
Cancer therapy market: L1+L2
Annotation 2; Label: BaseInstaller; Date: 2003-02-20 14:09:09
Casodex; Antiandrogens L2B2
Annotation 3; Label: BaseInstaller; Date: 2003-02-20 14:09:59
Arimidex; Aromatase inhib. L2B3
Page 16
- --------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date: 2003-02-20 14:17:54
Thinfection world market is an AstraZeneca estimation
Page 17
- --------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date: 2003-02-20 14:19:16
Total R-class
Annotation 2; Label: BaseInstaller; Date: 2003-02-20 14:20:45
Symbicort: R3f1
Annotation 3; Label: BaseInstaller; Date: 2003-02-20 14:22:49
Pulmicort Respules. US NPA data
Annotation 4; Label: BaseInstaller; Date: 2003-02-20 14:23:21
Oxis. R3A3
Annotation 5; Label: BaseInstaller; Date: 2003-02-20 14:24:40
Rhinocort Aqua. RX % of R1A1
Page 18
- --------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date: 2003-02-20 14:27:15
CNS therapies: N2C, N3A, N4A, N5, N6, N7
Annotation 2; Label: BaseInstaller; Date: 2003-02-20 14:53:09
Seroquel, Antipsychotic market N5A
Annotation 3; Label: BaseInstaller; Date: 2003-02-20 14:54:03
Zomig. Share of N2C
Page 19
- --------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date: 2003-02-20 14:57:32
Pain control Market, AZ defined:
M1A, M2A, Narcotics, Weak Opioids, Simple analgetics, N2C, Neurontin (60% US,
30% EU and 10% RoW)
Annotation 2; Label: BaseInstaller; Date: 2003-02-20 14:58:17
Anaesthetic market: N1
Annotation 3; Label: BaseInstaller; Date: 2003-02-20 15:19:59
Diprivan, N1A
Page 20
- --------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date: 2003-02-20 15:22:02
Nexium. Share of A2B2 TRX
Annotation 2; Label: BaseInstaller; Date: 2003-02-20 15:36:51
Zestril TRX share of C9A
Annotation 3; Label: BaseInstaller; Date: 2003-02-20 15:38:51
Toprol-XI TRX share of C7A
Annotation 4; Label: BaseInstaller; Date: 2003-02-20 15:40:52
Casodex: L2B2
Page 21
- --------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date: 2003-02-20 15:45:37
Oncology = L1+L2
Annotation 2; Label: BaseInstaller; Date: 2003-02-20 15:47:42
All countries: Nexium share of A2B2;
Symbicort share of R3F1
Page 22
- --------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date: 2003-02-20 15:49:18
Casodex share of L2B2
Annotation 2; Label: BaseInstaller; Date: 2003-02-20 15:49:52
Seroquel share of N5A1
Page 24
- --------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date: 2003-02-20 16:28:05
Nexium share of A2B2
Page 25
- --------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date: 2003-02-20 16:26:28
Symbicort share of R3F1
Page 26
- --------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date: 2003-02-20 16:29:18
Seroquel share of N5A1
Annotation 2; Label: BaseInstaller; Date: 2003-02-20 16:30:06
Zomig share of N2C1
Annotation 1; Label: BaseInstaller; Date: 2003-02-20 16:55:57
Pages 34-40 not attached in this document.
Pages 40-43 from last year's Financial Review, according to US requirements.
Rest of Annual report no market data included.
Page 27
- --------------------------------------------------------------------------------
Annotation 1; Label: BaseInstaller; Date: 2003-02-20 16:41:37
Pages 56 to 113 not attached in this document/EJ